Abstract
Twenty-three patients with rheumatoid arthritis participated in a double-blind crossover investigation of ketoprofen (Orudis) and indomethacin. Ratings which assessed the degree of joint involvement showed consistently greater improvement with Orudis, and side-effects occurred with less frequency. The majority of patients expressed a definite preference for Orudis.